Related Experiment Video
Updated: Jun 20, 2026
06:56
Development and Application of Rapamycin-regulated Tyrosine Phosphatases
Published on: September 6, 2024
[Effect of rapamycin on leukemia cell lines]
1Department of Hematology, The Second Hospital, Hebei Medical University, Shijiazhuang 050000, Hebei Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|August 25, 2009
Summary
Rapamycin effectively inhibits proliferation and induces apoptosis in KG1 leukemia cells by decreasing mTOR mRNA expression. Other leukemia cell lines, K562 and U937, showed less sensitivity to rapamycin treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Leukemia is a significant hematological malignancy.
- Targeting cell proliferation pathways is crucial for leukemia treatment.
- The mechanistic target of rapamycin (mTOR) pathway is implicated in cancer cell growth.
Purpose of the Study:
- To investigate the impact of rapamycin on leukemia cell proliferation and cell cycle.
- To analyze changes in mTOR mRNA expression following rapamycin treatment.
- To determine the sensitivity of different leukemia cell lines to rapamycin.
Main Methods:
- Treatment of KG1, K562, and U937 leukemia cell lines with varying concentrations of rapamycin.
- MTT assay to assess cell proliferation.
- Real-time quantitative PCR to measure mTOR mRNA expression.
- Cell cycle analysis to observe G(0)/G(1) phase arrest and apoptosis.
Main Results:
- Rapamycin demonstrated a significant inhibitory effect on KG1 cell proliferation at 20 nmol/L.
- KG1 cells exhibited G(0)/G(1) phase arrest, increased apoptosis, and reduced mTOR mRNA levels.
- K562 and U937 cell lines showed no significant response to rapamycin treatment.
Conclusions:
- Rapamycin effectively inhibits leukemia cell proliferation, particularly in KG1 cells.
- KG1 cells are sensitive to rapamycin, indicating potential therapeutic value.
- Differential sensitivity among leukemia cell lines suggests specific pathway involvement.
